
SCHOTT AG
SCHOTT
SCHOTT AG is a globally leading manufacturer of specialty glass and glass-ceramics, headquartered in Mainz, Germany, with a history dating back to 1884. The company's core glass-substrate business spans high-tech applications including optical glass, semiconductor-grade specialty substrates, pharmaceutical packaging, and industrial glass-ceramics. In fiscal year 2025, SCHOTT generated €2.83 billion in revenue, with its publicly listed subsidiary SCHOTT Pharma contributing €986 million. The company employs 17,392 people across more than 30 countries and operates over a dozen advanced production and R&D facilities worldwide, producing more than 13 billion pharmaceutical injection containers annually.
Strengths: SCHOTT's foundation-owned structure ensures long-term R&D investment without short-term shareholder pressure, enabling mastery of zero-expansion glass-ceramics and ultra-pure optical glass melting. Its dominant position in pharmaceutical vials and syringes, combined with cutting-edge capabilities in semiconductor and aerospace-grade substrates, provides diversified revenue streams. The company's global manufacturing footprint in over 30 countries ensures supply chain resilience and proximity to key customers.
Weaknesses: SCHOTT's reliance on specialty niches limits its scale compared to mass-market glass producers, while its foundation ownership structure can slow decision-making. The company faces intense competition from Asian rivals in display and optical glass, and its pharmaceutical segment is subject to regulatory and healthcare policy risks.Read MoreShow Less
Strengths: SCHOTT's foundation-owned structure ensures long-term R&D investment without short-term shareholder pressure, enabling mastery of zero-expansion glass-ceramics and ultra-pure optical glass melting. Its dominant position in pharmaceutical vials and syringes, combined with cutting-edge capabilities in semiconductor and aerospace-grade substrates, provides diversified revenue streams. The company's global manufacturing footprint in over 30 countries ensures supply chain resilience and proximity to key customers.
Weaknesses: SCHOTT's reliance on specialty niches limits its scale compared to mass-market glass producers, while its foundation ownership structure can slow decision-making. The company faces intense competition from Asian rivals in display and optical glass, and its pharmaceutical segment is subject to regulatory and healthcare policy risks.
In the press
All coverage →5 latest headlines1- Deutsche Bank cuts Schott Pharma stock to Hold and raises target to EUR 25.00 - ad-hoc-news.dewww.ad-hoc-news.de2026-10-20
- Judy Schott Obituary Oct 12, 2026 - Hoff Funeral & Cremation Servicewww.hofffuneral.com2026-10-12
- Jodi Lynn Schott Obituary Jul 29, 2026 - Cotter Funeral Homewww.cotterfuneralhome.com2026-07-29
- Tom Schott - Purdue Universitywww.purdue.edu2026-07-17
- Christine A Schott - Pollock-Randall Funeral Homepollockrandall.com2026-07-03
• Pharmaceutical Packaging — Borosilicate glass vials, cartridges, and syringes for injectable drugs, produced at a scale of over 13 billion units annually.
• Glass-Ceramics & Industrial Ceramics — Zero-expansion glass-ceramics e.g., ZERODUR® for astronomical telescopes, semiconductor lithography, and high-temperature industrial applications.
• Semiconductor & Aerospace Substrates — Ultra-thin, high-purity glass substrates for advanced packaging, MEMS, and aerospace optical systems.
• Food & Pharma Grade Glass Powders — Specialty glass powders and granulates for pharmaceutical excipients, food additives, and cosmetic applications.
Quick Facts
Headquarters
Mainz, Germany
Founded
1884
Employees
17,392
Revenue
€2.8 B (FY2025)
Factories
Over a dozen core specialty glass manufacturing plants and R&D centers globally
Presence
30+ countries
Categories
9 categories · scroll for more
Related
Similar listed companies
- Nvidia Corporation· $4.5 T
- Taiwan Semiconductor Manufacturing Company Limited ( TSMC )· $1.9 T
- Samsung Electronics Co., Ltd.· $1.1 T
- Micron Technology, Inc.· $780 B
- ASML Holding N.V.· $574 B
- Cisco· $370 B
Data Sources & Methodology
This corporate profile is compiled from publicly available sources including company annual reports, SEC/regulatory filings, official press releases, and verified third-party industry databases. Financial figures reflect the most recent fiscal year disclosures and are cross-validated across multiple independent references.
VerityRank Score is calculated using a proprietary multi-dimensional model evaluating market presence, financial strength, operational scale, innovation capacity, and brand influence. Individual dimension scores are normalized against industry peers and updated quarterly.
Disclaimer: This profile is for informational purposes only. VerityRank makes no warranties regarding completeness or timeliness. This content does not constitute investment advice or endorsement.
Key references: Official Website , SCHOTT Official Website
Wikipedia – SCHOTT AG
SCHOTT Investor Relations
Reuters – SCHOTT Pharma (1SXP.DE)
